RecruitingPhase 1NCT04192344
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor
Studying Tenosynovial giant cell tumor
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Abbisko Therapeutics Co, Ltd
- Principal Investigator
- Siqing Fu, MDM.D. Anderson Cancer Center
- Intervention
- ABSK021(drug)
- Enrollment
- 276 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (17)
- Precision NextGen Oncology, Beverly Hills, California, United States
- SCRI at HealthOne, Denver, Colorado, United States
- The Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- Beijing Jishuitan Hospital, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Sun Yat-sen University, Guangdong, Guangzhou, China
- Hebei Medical University Third Hospital, Shijiazhuang, Hebei, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- The First Affiliated Hospital of Zhengzhou Universtity, Zhengzhou, Henan, China
- Jiangsu Province Hospital, Nanjing, Jiangsu, China
- Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
- Liaoning Cancer Hospital, Shenyang, Liaoning, China
- Huashan Hospital of Fudan University, Shanghai, Shanghai Municipality, China
- Shanghai Sixth People's Hospital, Shanghai, Shanghai Municipality, China
- Xi'an Hong Hui Hospital, Xian, Shanxi, China
- +2 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04192344 on ClinicalTrials.govOther trials for Tenosynovial giant cell tumor
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07499362Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER)Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- RECRUITINGPHASE4NCT07315841Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor SurgeryShanghai Jiao Tong University Affiliated Sixth People's Hospital
- RECRUITINGNCT07075471Tenosynovial Giant Cell Tumor (TGCT) Real-World Participant Experience With VimseltinibDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE3NCT05417789Study of Emactuzumab for Tenosynovial Giant Cell Tumor (TGCT)SynOx Therapeutics Limited
- ACTIVE NOT RECRUITINGPHASE3NCT05804045Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)Abbisko Therapeutics Co, Ltd
- ACTIVE NOT RECRUITINGPHASE3NCT05059262Study of Vimseltinib for Tenosynovial Giant Cell TumorDeciphera Pharmaceuticals, LLC
- ACTIVE NOT RECRUITINGPHASE2NCT04703322A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in JapanDaiichi Sankyo Co., Ltd.
- RECRUITINGNCT04635111A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) TreatmentDaiichi Sankyo